The biosimilar firms won’t be able to challenge the great convenience of the subcutaneous Herceptin, as they will be launching intravenous-only biosimilars. That means the biosimilar competitors ...

which is currently given via intravenous (i.v.) infusion. As a line extension, it expands the blockbuster drug franchise and extends the patent protection for Herceptin—a strategy Roche could ...

By the late ’90s, a drug called Herceptin that targeted the HER2 receptor, sped into the clinic on ... Lab safety rules dictate that one must tie back long hair. Rosemarie Hansen learned the hard way ...

ENHANZE can shorten the dose administration time of intravenous drugs when administered subcutaneously, from hours to minutes. • Herceptin SC administration reduces delivery time from ~30 ...

The European Commission (EC) has approved Roche’s Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for post-surgery (adjuvant) treatment of adult patients with ...

The subcutaneous Perjeta-Herceptin formulation, Phesgo, was a top driver of sales growth in the first quarter of 2025.